FluidForm Bio successfully demonstrates advancements in engineered heart tissues with FRESH™ 3D bioprinting

FluidForm Bio, a leader in developing life-like human tissue to treat disease, shares recent advancements in building human cardiac tissues using FRESH 3D bioprinting.

Recently published in APL Bioengineering, the research article FRESH 3D bioprinted cardiac tissue, a bioengineered platform for in vitro pharmacology addresses the critical need for a predictive model of human cardiac physiology in drug development. There are significant gaps in existing models due to their incomplete recapitulation of adult human cardiovascular physiology. FluidForm Bio has demonstrated potential for bridging this gap using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in three-dimensional tissue structure.

"We are not aware of any other biofabrication or tissue engineering approaches that can achieve comparable cell densities and uniaxial alignment on the market today, both of which contribute to more advanced physiologic function" said FluidForm Bio CTO and Co-founder Adam Feinberg.

The FRESH technology overcomes many of the limitations of other engineered cardiac tissues because it enables a high degree of cardiomyocyte alignment while minimizing hypoxia and cell death. Furthermore, by leveraging robotic fabrication, tissues are highly viable and reproducible, maintaining functional response across tissues and batches.

This study was conducted by scientists at FluidForm and Merck & Co.. This is further evidence that we build the most lifelike tissue in the world with FRESH. As we develop tissue therapeutic applications on this platform, we are thrilled to collaborate with top scientists and look forward to sharing further data."

Mike Graffeo, CEO and Co-founder, FluidForm Bio

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    FluidForm Bio™. (2024, January 11). FluidForm Bio successfully demonstrates advancements in engineered heart tissues with FRESH™ 3D bioprinting. News-Medical. Retrieved on October 31, 2024 from https://www.news-medical.net/news/20240111/FluidForm-Bio-successfully-demonstrates-advancements-in-engineered-heart-tissues-with-FRESHe284a2-3D-bioprinting.aspx.

  • MLA

    FluidForm Bio™. "FluidForm Bio successfully demonstrates advancements in engineered heart tissues with FRESH™ 3D bioprinting". News-Medical. 31 October 2024. <https://www.news-medical.net/news/20240111/FluidForm-Bio-successfully-demonstrates-advancements-in-engineered-heart-tissues-with-FRESHe284a2-3D-bioprinting.aspx>.

  • Chicago

    FluidForm Bio™. "FluidForm Bio successfully demonstrates advancements in engineered heart tissues with FRESH™ 3D bioprinting". News-Medical. https://www.news-medical.net/news/20240111/FluidForm-Bio-successfully-demonstrates-advancements-in-engineered-heart-tissues-with-FRESHe284a2-3D-bioprinting.aspx. (accessed October 31, 2024).

  • Harvard

    FluidForm Bio™. 2024. FluidForm Bio successfully demonstrates advancements in engineered heart tissues with FRESH™ 3D bioprinting. News-Medical, viewed 31 October 2024, https://www.news-medical.net/news/20240111/FluidForm-Bio-successfully-demonstrates-advancements-in-engineered-heart-tissues-with-FRESHe284a2-3D-bioprinting.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.